マウスにおける多発性硬化症のEAEモデルにおける視神経炎と脳炎症の生物発光と近赤外イメージング

Executive Industry Relevance

Non-invasive bioluminescence and near-infrared imaging in the EAE mouse model enables real-time quantification of optic neuritis and brain inflammation, surpassing traditional clinical scoring. This approach provides actionable insights into disease progression and therapeutic efficacy, supporting predictive confidence at key discovery and preclinical inflection points. The method enhances translational continuity for neuroinflammatory disease portfolios by enabling robust, quantitative, and longitudinal assessment of CNS pathology in vivo.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables direct visualization and quantification of neuroinflammatory processes in living disease-relevant models.
• Supports mechanistic de-risking by distinguishing optic neuritis and brain inflammation from general motor deficits.
• Facilitates functional target validation by correlating imaging signals with therapeutic intervention effects.

Screening & Assay Development

• Provides standardized, reproducible imaging readouts for compound efficacy screening in neuroinflammation.
• Delivers quantitative outputs that can be benchmarked across studies and time points.
• Enables scalable, high-throughput assessment of candidate therapeutics in preclinical models.

Translational & Preclinical Research

• Aligns imaging biomarkers with clinical manifestations such as optic neuritis, supporting translational biomarker strategies.
• Maintains continuity from early discovery through preclinical validation by enabling longitudinal monitoring.
• Reduces biological risk by providing robust, non-invasive endpoints for advancement decisions.

Pipeline & Workflow Integration

This imaging platform integrates from early discovery through lead identification and preclinical validation in neuroinflammatory disease pipelines.

• Discovery Biology: Supports hypothesis testing and pathway clarification by enabling in vivo assessment of CNS inflammation and BBB integrity.
• Screening: Provides reproducible, quantitative imaging outputs for compound evaluation and dose-response studies.
• Analytics: Delivers region-of-interest quantification and statistical outputs for cross-condition comparisons.
• Translational Research: Bridges preclinical and clinical endpoints by modeling optic neuritis and BBB disruption relevant to MS patients.
• Enterprise Reuse: Offers a reusable imaging workflow adaptable to other neuroinflammatory and CNS disease models.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in neuroinflammation studies.
• Operational Value: Standardizes imaging protocols for reproducibility and scalability across studies.
• Strategic Value: Enables informed go/no-go decisions and capital-efficient portfolio management.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of neuroinflammatory disease assets.

Implementation Considerations

• Requires expertise in in vivo imaging and neuroimmunology model handling.
• Needs access to bioluminescence and near-infrared imaging instrumentation and analysis software.
• Demands cross-team standardization of imaging protocols and ROI quantification.
• Adaptation may be needed for different mouse strains or CNS disease models.
• Auto-fluorescence in near-infrared imaging necessitates spectral unmixing for accurate quantification.

Biopharma FAQs